Westport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, has today issued the following Letter to Shareholders: Dear Shareholders, As the new CEO of BioSig, I am committed to keeping our shareholders updated to the best of my ability on the progress of our Company. Our new management team is firmly committed to both restoring and creating ...

Westport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, has today issued the following Letter to Shareholders: Dear Shareholders, As the new CEO of BioSig, I am committed to keeping our shareholders updated to the best of my ability on the progress of our Company. Our new management team is firmly committed to both restoring and creating ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdi ...

Westport, CT, May 03, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "the Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced new appointments to its now fully constituted board of directors (the "Board"), which is comprised of a total of five (5) directors, three (3) of whom are classified as independent directors. The final compositions of the committees to the Board will be determi ...

Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer ("CEO"), effective immediately.  Additionally, Mr. Amato will serve on the Company's Board of Directors, which is currently being assembled.  Recall, that on April 4, 2024, the Co ...

公司产品与技术 - BioSig Technologies是一家拥有先进数字信号处理技术平台的医疗器械公司，专注于提供心律失常治疗方面的见解[356] - 公司的首款产品PURE EP™ System是一种经过FDA 510(k)认证的非侵入式二类设备，旨在提供前所未有的信号清晰度和精度，为实时可视化心内信号铺平道路[357] - PURE EP™ System捕获关键心脏信号，即使是最复杂的信号，旨在增强临床决策和改善所有类型心律失常的临床工作流程[358] - 公司拥有36项已发放/允许的实用专利，25项美国和国外实用专利申请，以及30项全球设计专利，涵盖PURE EP系统的各个方面[359] - 公司于2023年底推出PURE EP™软件版本7，代表公司数字信号处理技术的最先进版本，但销售受限于研究合作伙伴[360] 公司发展与战略合作 - 公司计划通过与已在心电生理领域拥有建立的合作伙伴合作，增加PURE EP在医院系统中的渗透率[361] - 公司计划继续推广PURE EP系统和其他核心技术应用，并通过出售额外的股权证券、债务或战略合作伙伴的资本流入筹集资金[416] 股票及财务状况 - 公司进行了股票逆向拆分，每十股合并为一股，股票代码仍为“BSGM”[362] - 由于未能恢复股价符合纳斯达克上市规则，公司面临被纳斯达克摘牌的风险[366] - 公司进行了大规模裁员，包括首席运营官、首席商务官等离职，目前只有CEO和少数员工[372] - 公司与某些认可的投资者签订了证券购买协议，出售了260,720股普通股和购买130,363股普通股的认股权证[381] - 公司于2023年12月31日结束的12个月中，收入为18美元，较2022年同期的286美元下降[392] - 2023年12月31日结束的12个月中，研发支出为5,092美元，较2022年同期的5,821美元下降[396] - 2023年12月31日结束的12个月中，总体和行政支出为23,077美元，较2022年同期的21,380美元增加[399] - 2023年12月31日结束的12个月中，净亏损为29,050美元，较2022年同期的27,271美元增加[411] - 截至2023年12月31日，BioSig AI Sciences的非控股权益为84.5%[409] - 2023年，BioSig Technologies, Inc.的可用净亏损为29,050美元[411] - 截至2023年12月31日，公司累计赤字约为2.45亿美元[414] - 公司预计将继续从事研究和开发、市场营销和商业化支出，以及一般和行政支出将在未来增加[419] - 公司未来的资本需求将取决于多个因素，包括产品候选品的研发进展、监管批准的时间和结果、准备、提交、审查、维护、保护和执行专利权和其他知识产权的成本[420] 股票发行与投资 - 公司于2023年11月8日与机构投资者签订证券购买协议，通过注册直接发行（“Offering”）出售了699,693股公司普通股，每股面值为0.001美元，以及购买最多699,693股普通股的A类认股权证（“Series A Warrants”）和购买最多699,693股普通股的B类认股权证（“Series B Warrants”）[1] - 公司向放置代理支付了7.0%的募集总收益现金费用和1.0%的管理费用，此外还支付了50000美元的不可核算费用和15950美元的清算费用[2] - 该公司通过发行S-3表格的注册直接发行了股票和认股权证，募集净收益约为220万美元[3] - 公司于2024年1月12日与某些认可的和机构投资者签订证券购买协议，募集总收益为104万美元[4] - 公司与Cantor Fitzgerald & Co.签订了控股股权发行销售协议，支付了3.0%的销售股票总收益佣金[5] - 公司于2023年8月18日至9月6日通过Cantor销售协议出售了21881股普通股，净亏损为899美元，交易成本为120430美元[6] - 公司于2023年9月15日至9月25日通过Ascendiant销售协议出售了28911股普通股，净收益为60876美元，交易成本为70806美元[7] - 公司于2024年3月7日向投资者和持股10%以上的关联方发行了50万美元的票据，票据到期日为2026年3月7日，年利率为12%[8] 现金流及投资活动 - 公司于2023年12月31日的营运现金流为17313美元，较2022年减少2392美元，主要是由于2023年现金运营支出减少[9] - 公司于2023年12月31日的投资活动现金流为186美元，较2022年增加18美元，主要用于购买办公家具、制造和测试设备、计算机设备和租赁改善[10]

Westport, CT, April 04, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today that it appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies.  BAIPC will work to deploy a series of solutions to transform BioSig's future course with additional strategies - including operations, sta ...

Westport, CT, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that physicians have completed over 100 cases with the Near Field Tracking ("NFT") algorithm, an innovative and proprietary feature recently launched on the Company's PURE EP™ Platform.  Available by subscription, PURE EP™'s NFT algorithm monitors cha ...

Westport, CT, Jan. 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. New York Time on Thursday, February 1, 2024. BioSig's common ...

Cost Savings Targeted to Reduce Cash Burn by 50% Core Strategy Shifts to Business Development and Distribution Partnerships Westport, CT, Jan. 30, 2024 (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced a workforce reduction, intended to reduce annual cash burn by 50%.  The Company is reducing its internal workforce, which is ...